GALT

Galectin Therapeutics Inc.

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. It also engages in developing GM-CT-01, which is in pre-clinical development stage for the treatment of cardiac and vascular fibrosis, as well as focuses on developing belapectin for the treatment of psoriasis, and lung and kidney fibrosis. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

Galectin Therapeutics Inc. (GALT) is rated C+ (2.5/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Momentum (B); its weakest is Growth (D+). The rating has held at C+ for 3 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.5 / 5.0
C+
Value
C+
Factor Score 2.5 / 5.0
Growth
D+
Factor Score 1.8 / 5.0
Profitability
C
Factor Score 2.3 / 5.0
Momentum
B
Factor Score 3.4 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -2.0
EV / EBITDA N/A
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M -6.8%
Price Return 12M -36.7%
Catalyst Signal 0.00
Market Cap $331.8M
TTM Revenue N/A
Price / Sales N/A
ROE N/A

Historical Factor Score Progression

Held C+ for 3 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-12 C+ (2.5) D+ (1.8) C (2.3) B (3.4) C+ (2.6) C+ (2.5)
2026-11-05 C+ (2.5) D+ (1.8) C (2.3) B+ (3.6) C+ (2.7) C+ (2.6)
2026-10-29 C+ (2.5) D+ (1.8) C (2.4) B+ (3.6) C+ (2.7) C+ (2.6)
2026-10-22 C+ (2.5) C- (1.9) C (2.4) B (3.4) C+ (2.6) C+ (2.5)
2026-10-15 C+ (2.5) D+ (1.8) C (2.4) B- (2.9) C+ (2.6) C (2.5)
Page 1 of 4